Aristotle University Of Thessaloniki (AUTH)
Μελέτη αποτελεσματικότητας των ενδοναρθηκών και των αεροθαλάμων με τεχνολογία αποδέσμευσης κυτταροστατικού φαρμάκου σε βλάβες των κνημιαίων αρτηριών σε διαβητικούς ασθενείς με κρίσιμη ισχαιμία κάτω άκρων
Abstract
dc:descriptionBackground: To report the comparative safety and efficacy of infrapopliteal angioplasty with a polymer-free drug eluting stent and a paclitaxel drug coated balloon in diabetic patients with critical limb ischemia (CLTI). Methods: Consecutive patients with diabetes and CLTI requiring infrapopliteal endovascular intervention were recruited prospectively in a tertiary centre to undergo angioplasty and primary stenting using the Cre8 sirolimus-eluting stent or paclitaxel balloon angioplasty between January 2018 - October 2020. All patients were followed-up for at least 12 months. All patients were Rutherford category V and had at least one patent infrapoliteal artery. Forty-three infrapopliteal arteries had stenosis and 15 are occluded. The primary outcome measure was target lesion patency (<50% restenosis). Clinically driven target lesion revascularisation (CD-TLR), amputations, Rutherford stage, and mortality were also recorded prospectively.Results: 54 patients (58 target lesions; median age: 69 years, 74% male) were included [27 undergoing primary stenting with the Cre8 device (main group) vs. 27 treated with a paclitaxel-coated balloon (historical controls)]. Technical success was 100%. Primary patency at 12 months was 81% in the Cre8 group vs. 71% in the control group (p=0.498). Overall, 4 (15%) patients in the Cre8 group vs. 3 (11%) patients in the control group underwent a major amputation within 12 months (p=1.0). CD-TLR (all endovascular) did not differ between groups at 12 months (4% Cre8 group vs. 10% control group, p= 0.599). Rutherford stage improvement at 12 months was superior for the Cre8 group (52% vs. 15% improved by at least one stage, p=0.039). One year mortality was 15% in the Cre8 group vs. 22% in the control group, p=0.726. Conclusion: Infrapopliteal angioplasty and primary stenting with the Cre8 stent is feasible and safe in patients with diabetes and CLTI. When compared to patients undergoing angioplasty with a paclitaxel-coated balloon, there were no significant differences regarding primary patency, CD-TLR, major amputations, and mortality at 12 months. Those treated with a Cre8stent were more likely to have an improvement in their Rutherford stage.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2023
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Tigkiropoulos, Konstantinos
- Τιγκιρόπουλος, Κωνσταντίνος
Subjects
dc:subject × 17- Περιφερική αρτηριακή νόσος
- Κρίσιμη ισχαιμία κάτω άκρων
- Ενδαγγειακή αγγειοχειρουργική
- συσκευές με έκλυση φαρμάκου
- Πακλιταξέλη
- Σιρολιμους
- Peripheral arterial disease
- Critical limb ischemia
- drug eluting devices
- Paclitaxel
- Sirolimus
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Χειρουργική
- Clinical Medicine
- Medical and Health Sciences
- Surgery
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/53109